Elsevier

Blood Reviews

Volume 29, Supplement 1, June 2015, Pages S1-S3
Blood Reviews

Introduction and overview

https://doi.org/10.1016/S0268-960X(15)30001-1Get rights and content

Section snippets

Conflict of interest statement

PM Mannucci has received speaker fees for participation at educational meetings organised by Bayer, Grifols, Kedrion Biopharma and Novo Nordisk. F Peyvandi has received honoraria for participating as a speaker at educational meetings organised by Bayer, Baxter, CSL Behring and Novo Nordisk; she has received research grant funding from Biotest, Novo Nordisk and Kedrion, and consulting fees from Kedrion, LFB and Novo Nordisk.

Acknowledgements

Sharon Eastwood of PAREXEL, a medical writer supported by funding from Novo Nordisk Health Care AG, provided drafts and editorial assistance to the authors during preparation of this editorial.

First page preview

First page preview
Click to open first page preview

References (42)

  • PM Mannucci et al.

    Recombinant factor VIIa as haemostatic therapy in advanced liver disease

    Blood Transfus

    (2013)
  • NovoSeven®

    Summary of Product Characteristics

  • U Hedner et al.

    Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors

    J Clin Invest

    (1983)
  • NovoSeven Highlights of Prescribing Information

  • A Coppola et al.

    Treatment of hemophilia: a review of current advances and ongoing issues

    J Blood Med

    (2010)
  • H Chambost et al.

    Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry

    Haemophilia

    (2013)
  • K Kavakli et al.

    Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial

    Thromb Haemost

    (2006)
  • NS Key et al.

    Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors

    Thromb Haemost

    (1998)
  • R Parameswaran et al.

    Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

    Haemophilia

    (2005)
  • P Salaj et al.

    Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors

    Haemophilia

    (2012)
  • G Young et al.

    Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

    Haemophilia

    (2008)
  • Cited by (0)

    View full text